Compare the effect of high and low doses of atorvastatin on the levels of high-sensitivity C-reactive protein in patients with acute coronary syndrome


  • Bijan Zamani Faculty of Medicine, Ardabil University of Medical Science, Ardabil
  • Behzad Babapour Faculty of Medicine, Ardabil University of Medical Science, Ardabil
  • Hosein Doustkami Faculty of Medicine, Ardabil University of Medical Science, Ardabil
  • Mirhashem Mousavi Faculty of Medicine, Ardabil University of Medical Science, Ardabil



Acute coronary syndrome, Atorvastatin, HS-CRP


Background: Findings of other researches indicate that inflammation process is one of the most important molecular interactions mediated in atherosclerosis and the inflammation indexes of plasma level such as high-sensitivity C-reactive protein (hs-CRP) is regarded to predict the risk of cardio-vascular diseases. According to various studies, statins are certainly effective in the prevention of atherosclerosis and anti-inflammatory role of atorvastatin by lowering effect on hs-CRP can be considered. The aim of this study was to compare the effect of high and low doses of atorvastatin on levels of hs-CRP in patients with acute coronary syndrome.

Methods: This is a clinical trial study that has been done on 180 patients with acute coronary syndrome who referred to Imam Khomeini hospital in Ardabil. Patients were divided in 2 groups randomly. Atorvastatin with low dose (20mg) and high dose (40mg) with routine treatments were given to first and second groups, respectively. The hs-CRP level was evaluated for all patients in hospitalized time and third month late. Data were collected and analyzed by statistical methods in SPSS.19.

Results: Of all patients, 40 patients (22.2%) was assayed with STEMI, 8 patients (4.4%) with N/Q WMI and132 patients (73.3%) with U/A. 125 patients (69.4%) were male and rest of them were female. The age average of patients was 59.1±8.1 years. 74 (41.1%) of patients had blood pressure and 35 (19.4%) use smoke. After three months, in group with low dose, 81 patients (90%) and in group with high dose 85 patients (94.4%) improved. The atorvastatin with high dose could significantly decrease the hs-CRP ratio with 40% more than other group with 13.3%.

Conclusions: In this study high dosage of atorvastatin could lessen significantly the hs-CRP and LDL ratio compared to atorvastatin with low dosage.


Mann, Zipes, Libby, Bonow. Braunwalds Heart disease, A textbook of cardiovascular medicine. 7th ed. Elsevier. 2005;4-17, 939-42,936-61

American heart association: 2003 heart and Stroke statistical update. Dallas, American heart association. 2003.

Frederck H. Cardiovascular disease Epidemiology, A Journey From the past into the future. Circulation. 1996;93:1755-64.

Newman WP, Strong JP, Johnson WD, Oalmann MC, Tracy RE, Rock WA. Community pathology of atherosclerosis and coronary heart disease in New Orleans. Morphologic findings in young black and white men. Laboratory investigation a journal of technical methods and pathology. 1981:44(6);496-501.

Ellis C, Devlin G, Matsis P. Acute coronary syndrome patients in New Zealand receives less invasive management when admitted to hospitals without invasive facilities. NZ Med J. 2004;117(1197):U954.

McGill HC Jr, McMahan CA, Herderick EE, Malcom GT, Tracy RE, Strong JP. Origin of atherosclerosis in childhood and adolescence. Am J Clin Nutr. 2000;72(5 Suppl):1307S-15S.

Blackburn H, Epstein F. History of the Council on Epidemiology and Prevention, American Heart Association. Circulation. 1995;1253-62.

World health report 2002: Reduction risk, promoting healthy life-Geneva, World health organization, 2002. Cigarette report for 2001, federal trade commission. 2003.

Cannon CP, Battler A, Brindis RG, Cox JL, Ellis SG, Every NR, et al. American college of cardiology key elements and definition for measuring the management and outcomes of patients with acute coronary syndrome. J Am Coll Cardiol. 2001;38(7):2114-30.

Fiebig RG, Hollander D, Ney R, Jeffery Boileau E, Ji LL. Training down-regulates fattyacid Strength and blood fat in obese zucker rats. Med SCi Spo Exer. 2002;34(7):1160-14.

Festa AD, Jr Agostino R, Howard G, Mykkanen L, Tracy RP, Haffner SM. Chronicsubclinical inflammation as part of the insulin resistance syndrome. The Insulin Resistance Atherosclerosis Study (IRAS). 2002;102:42-7.

Fairey AS, Courneya KS, Field CJ, Bell GJ, Jones LW, Martin BS. Effect of exercise training on C-reactive protein in postmenopausal breast cancer survivors: a randomized controlled. Brain Behav Immun. 2005;19(5):381-8.

Goodarzi MT, Babaahmadi-Rezaei H, Kadkhodaei M, Haddadinezhad S. Relationship of serum adiponectin with blood lipids, HbA (1) c, and hs-CRP in type II diabetic postmenopausal women. J Clin Lab Anal. 2007;21(3):197-200.

Geffken DF, Cushman M, Burke GL, Polak JF, Sakkinen PA, Tracy RP. Association between physical activity and Markers of Inflammation in a Healthy Elderly Population. American J.ofepidemiology. 2001;153(3):242-50.

Isasi CR, Deckelbaum RJ, Tracy RP, Starc TJ, Berglund L, Shea S. Physical fitness and Creative protein level in children and young adults the Columbia University Biomarkers Study. Pediatrics. 2003;111:332-8.

Stauffer BL, Hoetzer GL, Smith DT, Desouza CA. Plasma C-reactive protein is not elevated in physically active postmenopausal women taking hormone replacement therapy. J. Appl. Physiol. 2004;96:143-8.

McCaig Lf, Burt CW. National hospital Ambulatory Medical Care Survey 2004 emergency department summary. Adv Data. 2006;(372):1-29

Beyranvand M, Kolahi A, Ghafelebashi S. Charactristics and final diagnosis of patients with primary diagnosis of acute coronary syndrome. JBUMS. 2008;10(3):76-82.

Hasdai D, Behar S, Wallentin L, Danchin N, Gitt AK, Boersma E, et al. A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin; the Euro heart survey of acute coronary syndromes (Euro Heart Survey ACS). Eur Heart J. 2002;23(15):1190-201.

Fox KA, Goodman SG, Klein W, Brieger D, Steg PG, Dabbous O, et al. Management of acute coronary syndromes. Variations in practice and outcome findings from the global registry of acute coronary events (GRACE). Eur Heart J 2002;23(15):1177-89.

Achar SA, Kundu S, Norcross WA. Diagnosis of acute coronary syndrome.Am Fam Physician. 2005;72(1):119-26.

Pavesi PC, Ottani F, Bologna F, Gaddi O, Alboni P, Galvani M. Epidemiology of acute coronary syndromes in cardiology departments of the Emilia Romagna region: the AI-CARE2 study. Ital Heart J Suppl. 2003;4(9):733-44.

Naghavi M. The picture of death in 18 provinces of Iran in 2001, Iran. Ministry of Health and Medical Educations publication. 2003;123.

Ellis C, Devlin G, Matsis P, Elliott J, Williams M, Gamble G, et al. Acute coronary syndrome patients in New Zealand receive less invasivemanagement when admitted to hospitals without invasive facilities. N Z Med J. 2004;117(1197): U954.

Navarro JF, Mora C, Muros M, García-Idoate G. Effects of atorvastatin on lipid profile and non-traditional cardiovascular risk factors in diabetic patients on hemodialysis. Nephron Clin Pract. 2003;95(4):c128-35.

Office of Development and Coordination for Statistical System, Ministry of Health and Medical Education, Deputy of research. Activities statistics of affiliated hospitals of Ministry of Health and Medical Education. Statistical Annals. 2002.

Rosenson RS, Freeman MW, Rind DM. Statins: Actions, side effects, and administration [Online]. 2011; Available from: URL: contents/ statinsactions-side/

Bakker-Arkema RG, Davidson MH, Goldstein RJ, Davignon J, Isaacsohn JL, Weiss SR, et al. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA. 1996;275(2):128-33.

Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol. 2003;92(2):152-60.

Vasilieva E, Kasyanova O, Shpektor A. The antiplatelet effect of atorvastatin in patients with acute coronary syndrome depends on the hs-CRP level. Acute Card Care. 2008;10(3):181-4.

Gupta A, Badyal DK, Jaison M, Chopra S. Effect of atorvastatin on hs-CRP in acute coronary syndrome. Br J Clin Pharmacol. 2008;66(3):411-3.

Chan DC, Watts GF, Mori TA, Barrett PH, Beilin LJ, Redgrave TG. Factorial study of the effects of atorvastatin and fish oil on dyslipidemia in visceral obesity. Eur J Clin Invest. 2002;32(6):429-36.

Macin SM, Perna ER, Farías EF, Franciosi V, Cialzeta JR, Brizuela M, et al . Atorvastatin has an important acute anti-inflammatory effect in patients with acute coronary syndrome: results of a randomized, double-blind, placebo-controlled study. Am Heart J. 2005;149(3):451-7.

Boonbaichaiyapruck S, Cheepudomwit S, Panjavenin P, Suthichaiyakul T, Moleelerkpoom W, Benjanuwatra T, et al. Effect of atorvastatin on LDL & hs-CRP in a selected Thai population. J Med Assoc Thai. 2008;91(8):1189-95.




How to Cite

Zamani, B., Babapour, B., Doustkami, H., & Mousavi, M. (2016). Compare the effect of high and low doses of atorvastatin on the levels of high-sensitivity C-reactive protein in patients with acute coronary syndrome. International Journal of Research in Medical Sciences, 4(9), 3895–3899.



Original Research Articles